Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/11000/35453

The role of rapid multiplex molecular syndromic panels in the clinical management of infections in critically ill patients: an experts-opinion document


Vista previa

Ver/Abrir:
 02 - Candel FJ et al crit Care.pdf

1,79 MB
Adobe PDF
Compartir:
Título :
The role of rapid multiplex molecular syndromic panels in the clinical management of infections in critically ill patients: an experts-opinion document
Autor :
Candel, Francisco Javier  
Canton, Rafael  
Canton, Rafael  
Del Pozo, Jose L  
Galán Sánchez, Fátima  
Navarro, David
RODRIGUEZ DIAZ, JUAN CARLOS  
RODRIGUEZ DIAZ, JUAN CARLOS  
Rodríguez Aguirregabiria, Montserrat Aránzazu  
Suberviola, Borja  
Zaragoza, Rafael  
Editor :
BioMed Central
Departamento:
Departamentos de la UMH::Producción Vegetal y Microbiología
Fecha de publicación:
2024-12-30
URI :
https://hdl.handle.net/11000/35453
Resumen :
Rapid multiplex molecular syndromic panels (RMMSP) (3 or more pathogens and time-to-results < 6 h) allow simultaneous detection of multiple pathogens and genotypic resistance markers. Their implementation has revolutionized the clinical landscape by significantly enhancing diagnostic accuracy and reducing time-to-results in different critical conditions. The current revision is a comprehensive but not systematic review of the literature. We conducted electronic searches of the PubMed, Medline, Embase, and Google Scholar databases to identify studies assessing the clinical performance of RMMSP in critically ill patients until July 30, 2024. A multidisciplinary group of 11 Spanish specialists developed clinical questions pertaining to the indications and limitations of these diagnostic tools in daily practice in different clinical scenarios. The topics covered included pneumonia, sepsis/septic shock, candidemia, meningitis/encephalitis, and off-label uses of these RMMSP. These tools reduced the time-to-diagnosis (and therefore the time-to-appropriate treatment), reduced inappropriate empiric treatment and the length of antibiotic therapy (which has a positive impact on antimicrobial stewardship and might be associated with lower in-hospital mortality), may reduce the length of hospital stay, which could potentially lead to cost savings. Despite their advantages, these RMMSP have limitations that should be known, including limited availability, missed diagnoses if the causative agent or resistance determinants are not included in the panel, false positives, and codetections. Overall, the implementation of RMMSP represents a significant advancement in infectious disease diagnostics, enabling more precise and timely interventions. This document addresses relevant issues related to the use of RMMSP on different critically ill patient profiles, to standardize procedures, assist in making management decisions and help specialists to obtain optimal outcomes
Palabras clave/Materias:
Critically ill patient
Infection
Multidrug resistant pathogens
Septic shock
Sepsis
Bloodstream infection
Syndromic molecular diagnosis
Tipo de documento :
info:eu-repo/semantics/article
Derechos de acceso:
info:eu-repo/semantics/openAccess
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
DOI :
https://doi.org/10.1186/s13054-024-05224-3
Aparece en las colecciones:
Artículos Producción vegetal y microbiología



Creative Commons La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.